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Objectives: Most industrialized countries strive to guarantee long term sustainabil-
ity for HIV antiretroviral treatment . By assessing the most relevant current predictors 
of costs of antiretrovirals(HAART) might represent the first step to understand spend-
ing drivers and to plan cost reduction strategies. MethOds: A retrospective sample 
of HIV outpatients followed at 5 Italian Hospitals in 2012 was collected. Demographic 
features, current HIV viral load, current and Nadir CD4 T-celI counts, time from HIV 
diagnosis, AIDS-defining events, HAART line and HCV coinfection were taken into 
consideration. Individual ARV regimen-costs were based on local pharmacy data-
sets from December, 2011, and log-transformed in the final multivariate models. 
Univariate analyses were performed to identify potential predictors and stepwise 
multivariate regressions were used to identify independent predictors of higher indi-
vidual costs, using Stata 10.1 package. Results: We included 2044 patients, 69.0% 
males, mean age 47.2±10.0 years; 33.4% HCV-coinfected, mean time from HIV diag-
nosis 13.3±7.9 years, mean nadir CD4 T cell counts 239±169.3 cell/mm3; mean current 
CD4T-cell counts 590±302.6 cell/mm3, 30.8% AIDS classified. Patients on HAART were 
1,902 (93.0%),among treated patients, 19.0% presented an HIV-viremia> 50 c/mL. Mean 
annual individual HAART-costs were € 9,376±3,501 (782-29,852). At univariate analysis, 
a significant association was found between costs and age time from HIV diagno-
sis, previous AIDS diagnosis, HCV-coinfection current and Nadir CD4T-cell counts, 
HAART-line, HIV-viremia and site of care. In the final regression model, HAART costs 
showed independent and direct correlation with HAART lines (p< 0.001), detectable 
viremia (p< 0.001) and time from HIV diagnosis (p= 0.009); inverse correlation with 
Nadir CD4 T-cell counts (p= 0.01). Being treated at 2 of 5 centre was another predictor of 
higher costs.(P< 0.001). cOnclusiOns: Higher HAART-costs were strongly associated 
with previous treatment failures and detectable HIV-viremia; a more compromised 
immune status at clinical presentation and a longer duration of HIV infection showed 
independent contribution, focusing on timely diagnosis of HIV infection.
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Objectives: Develop model simulating economic implications of alternative treat-
ment strategies for acute bacterial skin and skin structure infections (ABSSSIs) 
with suspected Methicillin-Resistant Staphylococcus aureus (MRSA) that consid-
ers antibiotic switches, course duration, route of administration and location of 
care (LOC). MethOds: Discrete event simulation (DES) tracks patient pathways 
through various LOC (ED, inpatient, outpatient) during ABSSSI treatment for sus-
pected MRSA. Model assumes 60% of patients hospitalized. Multiple pathways are 
allowed: patients responding can move to outpatient to finish treatment, switch 
treatment at discharge or receive 2nd line treatment if not responding. Patients 
accrue resource use, time in LOC and costs. Hospital days obtained from analysis 
of Premier Hospital Database. Three cohorts created; all assigned to receive van-
comycin (VAN) 1st line therapy. Upon discharge, one cohort continued on VAN, one 
switched to oral linezolid (LIN), one to daptomycin (DAP) to complete treatment. 
Costs are from the Medicare perspective in 2012 USD. Results: Hospital plus out-
patient days range from 11.1 (VAN) to 14.5 (LIN); costs ranged from $6,983 (LIN) 
to $8,122 (VAN) with suspected MRSA. By comparison, reatment duration ranged 
from 9.97 (VAN) to 13.02 (LIN) and total costs ranged from $6,889 (LIN) to $9,354 
(VAN) when MRSA is not always suspected. Despite longer LIN treatment, costs are 
lower because of avoided infusion costs. Outpatient costs account for 22% (LIN) to 
33% (VAN) of total costs. Sensitivity analysis examined impact on cost when treat-
ment duration varied per drug labeling. Total costs varied from $6,756 to $7,158 
when duration of LIN ranges from 8 days to 12 days. cOnclusiOns: Treatment 
choice and LOC have major impact on ABSSSI resource use and costs. Suspected 
MRSA increases treatment duration and cost. Economic implications for payers and 
providers should be evaluated using models that capture these elements in view 
of long-acting lipoglycopeptide IV antibiotics in development that avoid repeated 
infusions and may allow for less inpatient treatment.
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Objectives: Adverse events (AEs) and premature treatment discontinuation of pro-
tease inhibitor (PI) therapy in the treatment of chronic hepatitis C (CHC) may mitigate 
the benefits of improved sustained virologic response. We use data from a recent study 
to estimate the economic impact of PI therapy in the cirrhotic non-responder popula-
tion. MethOds: In the Compassionate Use of Protease Inhibitors in viral C cirrhosis 
(CUPIC) study, patients with compensated cirrhosis and genotype 1 CHC were treated 
with boceprevir (n= 205) or telaprevir (n= 292) in combination with peginterferon alpha 
and ribavirin. The investigators reported safety and tolerability in an interim 16-week 
analysis. Using CUPIC data and micro-costing technique, we estimate the costs of treat-
ment-related hematologic and rash AEs by severity (Grades 2-4) and the cost of drug 
wastage using PI discontinuation rates due to serious AEs (SAEs) (7.3% boceprevir; 14.7% 
telaprevir). We surveyed 3 hepatologists to ascertain treatment patterns related to AEs 
and combined these estimates with cost data to compute mean costs per treatment 
group from the US payer perspective during the first 16 weeks of therapy. Results: The 
AE-related costs were $1,980 and $2,161 for telaprevir and boceprevir treated patients, 
respectively, for the first 28 days of treatment. Medication-related costs of premature 
discontinuation due to SAEs were estimated at $8,463 for telaprevir and $1,575 for 
visits, hospitalization days and costs associated with adverse events, which included 
medical services and medications. Results: The study included 1,081 patients who 
used at least one HCV medication (mean age of 46.4 years [SD= 10.7], 64.8% men). 
Peg-Riba only, Peg-Riba+boceprevir and Peg-Riba+telaprevir was used by 1,029 (95.2%), 
50 (4.6%) and 18 (1.7%) patients respectively. Fifty-seven patients (5.3%) required a 
subsequent HCV treatment during the study period. The mean duration of treatments 
was 30.4 weeks (SD= 16.1). During HCV treatment, the average number of health care 
resources per patient was 13.2 physician’s visits and procedures, 1.0 hospitalization 
day and 0.9 emergency visit. While receiving HCV treatment, 191 (17.7%) of patients 
required erythropoietin, 353 (32.7%) received rash treatments and 541 (50.0%) were 
treated for depression. Estimated costs associated with management of these three 
AE were CDN$10,834, CDN$78 and CDN$268 per patient respectively. cOnclusiOns: 
HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
PIN53
thE costs of maNagINg gENItal warts IN thE uk By dEvolvEd NatIoN: 
ENglaNd, scotlaNd, walEs aNd NorthErN IrElaNd
Chapman R.1, Coles V.A.H.2, Lanitis T.1, Carroll S.M.2
1Evidera, London, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
Objectives: Genital warts (GW), 90% of which are caused by human papillomavirus 
(HPV) types 6 and 11, are a significant problem in the UK. The cost of managing GW 
in 2010 was previously estimated at £52.4 million. The objective of this study was 
to estimate the cost of GW management up to 2012, and to determine the cost by 
UK jurisdiction. MethOds: Population statistics were obtained from the Office of 
National Statistics for the UK, England and Wales; the General Register Office and 
2011 census data for Scotland; and the Northern Ireland (NI) Statistics and Research 
Agency. Numbers of GW cases in genito-urinary medicine (GUM) clinics were 
obtained from the Health Protection Agency for the UK and England; the Information 
Services Division for Scotland; the Communicable Disease Surveillance Centre for 
Wales; and the Public Health Agency for NI. The number of cases treated in primary 
care was estimated from The Health Improvement Network database. Population 
statistics and GW cases were extrapolated by jurisdiction to 2012. The number of 
visits and therapy required for GW management were estimated by GUM experts 
for standard and hard-to-treat patients. Costs were obtained from the most recent 
National Health Service (NHS) Payment by Results tariffs, Personal Social Services 
Research Unit and British National Formulary. Results: The model estimated 
220,779 GW cases in the UK, costing £58.42 million annually (£265 per patient). For 
England, 157,693 cases were estimated costing £41.72 million; for Scotland 7,461 
cases costing £1.90 million; for Wales 7,091 cases costing £1.87 million; and for NI 
3,619 cases costing £0.95 million. cOnclusiOns: The full NHS costs for the man-
agement of GW have never before been estimated separately for each jurisdiction. 
The results of the model reveal a significant economic burden which is important 
to quantify when understanding the value of quadrivalent HPV vaccination.
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Objectives: The ANRS CO20-CUPIC study was designed to evaluate triple therapy 
(TT) efficacy and safety in HCV-cirrhosis treatment-experienced patients in the 
French Early Access Programme. A 60-week interim analysis has been reported 
confirming better clinical outcomes than double therapy in a real clinical setting. 
However, independently of the protease inhibitor (PI) used, boceprevir (BOC) or tel-
aprevir (TLV), treatment failure (TF) was reported in up to 60% of the patients. Little 
is known about these patients’ treatment cost: that of successfully treated patients 
can be generally calculated from the full course of PI treatment, but the cost of those 
who failed highly depends on TF timing. Our objective is to estimate the average PI 
cost/patient who failed treatment based on CUPIC study reported data. MethOds: 
Using reported data on ITT virological response and TF, BOC and TLV on-treatment 
rates over time were estimated. Based on this curve, the average PI treatment duration 
and average PI cost/patient who failed treatment were calculated. When not enough 
information about time to treatment discontinuation was available, the same con-
servative approach was applied for both drugs, considering the midpoint of the treat-
ment interval. Sensitivity analyses on the time to TF were performed to confirm the 
robustness of the results. Results: A total of 472 patients (72%) were included in the 
60-week interim analysis. Independently of the IP used, about 60% the patients who 
start treatment did not achieve viral cure and their estimated average PI treatment 
duration was 26 wks in BOC patients and 11 wks in TLV patients. The average PI cost/
patient who failed treatment with TLV (23.012€ ) was 26% higher than that of treatment 
with BOC (18.253€ ). The sensitivity analysis confirmed the robustness of the base case 
estimation. cOnclusiOns: In a scenario of comparable efficacy between both PIs, 
the resources wasted on TF acquire a great importance in selecting the least costly of 
the two alternatives. Based on CUPIC study reported data, the average PI cost/patient 
who failed treatment was significantly higher in TLV patients than in BOC patients.
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general hospital (PB 6M€ ). We chose 24 active ingredients (95 different antibiotics) 
that represent about 1/3 of total hospital antibiotics and 80% of the total anti-
biotics’ budget. We studied their consumption for the years 2011 and 2012 and 
calculated the costs based on the official drug pricelist and their price after the 
negotiation. Results: From 2011 to 2012 the discounts gained from each hospital 
were increased. Price negotiation does not apply in prototype drugs that their com-
panies are only obliged to offer a 5% rebate. Unfortunately, these medications are 
more expensive, represent 36% of the studied antibiotics’ cost and their consump-
tion was increased by 20%. But, the discounts for all the studied off-patent drugs 
and their generics were from 12.8% till 89.9%. Thus, the total cost saving for them 
was 33.2% at PAGNI, 26.0% at Evaggelismos and 43.1% at Tzaneio. The total benefit 
for the pharmaceutical expenditure was 3% for both PAGNI and Evaggelismos, and 
6% for Tzaneio. cOnclusiOns: Price negotiation is an effective mean of decreas-
ing the cost of off-patent and generic drugs but newer and expensive drugs get 
doctors’ preference, undermining the Pharmacy’s cost-saving effort.
PIN61
what arE thE clINIcal aNd EcoNomIc costs aNd BENEfIts of 
ImPlEmENtINg PoINt of carE tEsts for chlamydIa trachomatIs aNd 
NEIssErIa goNorrhoEa IN gENIto-urINary mEdIcINE clINIcs IN thE 
uNItEd kINgdom?
Turner K.M.1, Round J.2, Horner P.1, Macleod J.1, Goldenberg S.3, Deol A.4, Adams E.J.4
1University of Bristol, Bristol, UK, 2University College London, London, UK, 3Guy’s and St Thomas’ 
NHS Foundation Trust, London, UK, 4Aquarius Population Health, London, UK
Objectives: To estimate the costs and benefits of patient pathways incorporating 
a point of care nucleic acid amplification test (POC NAAT) for chlamydia and gonor-
rhoea in genito-urinary medicine (GUM) clinics in the UK compared with standard 
off-site laboratory testing. MethOds: We simulated 1.2 million men and women 
GUM clinic attendees based on GUMCAD reports from the UK (2011). A Markov 
model with Monte Carlo simulation in Microsoft Excel was developed to compare 
existing standard pathways of testing and treatment for chlamydia and gonorrhoea 
with a POC NAAT. We conducted sensitivity analyses to evaluate the robustness of 
the model findings. The primary outcome was the incremental cost-effectiveness 
ratio (ICER = £/QALY). Secondary outcomes included the number of inappropriate 
treatments, complications and transmissions averted and change in time from test 
to treatment. Results: The total cost of using the POCT in our cohort was £103.3 
million compared with £113.9 million for standard care. The ICER was -£4,182/QALY, 
making the new pathways cost saving. Nearly 100,000 inappropriate treatments 
might be avoided by using a POC NAAT. Patients receive diagnosis and treatment on 
the same day as testing, which may also prevent 162 cases of pelvic inflammatory 
disease and 17,561 transmissions. cOnclusiOns: Replacing standard laboratory 
tests for chlamydia and gonorrhoea with a POCT could be cost saving and patients 
would benefit from more accurate diagnosis and less unnecessary treatment. 
Overtreatment currently accounts for about a tenth of the reported treatments for 
chlamydia and gonorrhoea and POC NAATs would effectively eliminate the need 
for presumptive treatment.
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Objectives: Rotavirus (RV) causes highly contagious gastroenteritis especially in 
children under five years of age. Since 2006, two RV-vaccines are available in Europe 
(Rotarix® and RotaTeq®). We evaluated the cost-effectiveness of these vaccines for 
the German health care setting, inter alia to support an informed decision-making 
concerning a potential vaccination-recommendation. MethOds: A Markov Model 
was developed to evaluate the cost-effectiveness from the statutory health insur-
ance (SHI) (direct costs) and from the societal perspective (SHI plus indirect costs). 
Health outcomes considered were RV-cases prevented, RV-associated hospitalizations 
avoided, and quality-adjusted life-years (QALY) gained. RV-incidences were derived 
from the national mandatory disease reporting system. RV-vaccine efficacy was cal-
culated as pooled estimates based on data from randomized controlled trials. Costs 
(reference year 2010) were derived from official price catalogues. An annual discount 
rate of 3% for effects and costs was applied. The first five life-years were considered as 
model’s time horizon. Results: The base-case analysis (SHI-perspective) resulted in 
an incremental cost-effectiveness and cost-utility ratio (ICER) for Rotarix® of € 184 per 
RV-case prevented, € 2,457 per RV-associated hospitalization avoided, and € 116,973 
per QALY gained. For RotaTeq®, the results were slightly higher (€ 234, € 2,622, and € 
142,732, respectively). In sensitivity analyses parameter variation showed effects on 
the ICERs without changing the overall trend. A threshold analysis suggests that cost-
saving scenarios are possible with vaccine prices reduced by ~62-66%. When applying 
base-case scenario results to the 2012 birth-cohort with 80% vaccination coverage, an 
estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be 
prevented in this birth-cohort over 5 years for an incremental cost of 44.5-48.2 million 
Euros. cOnclusiOns: Routine RV-vaccination is expected to prevent a consider-
able number of RV-cases and RV-associated hospitalizations in Germany. Though, the 
amount of QALYs gained is low. With current vaccine prices, RV-vaccination is not a 
cost-saving preventive measure.
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boceprevir. Total costs of AE and discontinuation were $10,443 and $3,736 for telaprevir 
and boceprevir treated groups, respectively. The results were not sensitive to variation 
in treatment practices and costs. cOnclusiOns: The costs of treatment of cirrhotic 
non-responders during the first 16 weeks were estimated to increase by 18% over triple 
therapy costs due to AEs. These data indicate that the total cost per cure may be sub-
stantially higher than the drug costs and underscore the importance of evaluating total 
cost of HCV treatment when selecting new agents.
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Objectives: Current guidelines for the treatment of acute bacterial skin and skin 
structure infections (ABSSSI) recommend several treatment pathways based on the 
infection types and severity. The objective of this study is to establish the health 
care resource utilization (HRU) and costs associated with the most common patient 
treatment pathways in US. MethOds: The medical and pharmacy administrative 
claims of adult ABSSSI patients with continuous commercial or Medicare Advantage 
enrollment with Part D prescription drug coverage between 01 January 2009 and 
31 December 2011 were extracted from a large national health plan affiliated with 
OptumInsight. The four most common treatment pathways were identified based on 
the evidences of antibiotics over the entire ABSSSI treatment course. All four path-
ways start with vancomycin IV use during a hospital stay. At discharge, patients fol-
lowed one of four pathways: 1) continue IV vancomycin as an Outpatient Parenteral 
Antibiotic Therapy (OPAT); 2) switch to oral linezolid; 3) switch to daptomycin; or 4) 
switch to any oral antibiotic other than linezolid, clindamycin, or TMP-SMX. Health 
care resource utilization and costs were determined for each pathway. Results: A 
total of 1418 patients met all of inclusion/exclusion criteria. The majority of patients 
either continued Vancomycin IV (46.5%) or switched to oral linezolid (41.4%) at dis-
charge. Only about 12% of patients were switched to Daptomycin or other non-MRSA 
active oral antibiotics. The average ABSSSI-related total health care cost was $16,571 
for the entire ABSSSI treatment. Total costs were comprised of $12,519 (75.5%) for 
inpatient cost, $201 (1.2%) for emergency department (ED) visits, $879 (5.3%) for 
outpatient treatment/office visits, and $1,015(6.1%) for pharmacy claims cost. The 
costs overall and in various locations of care varied by pathway. cOnclusiOns: 
Inpatient treatment remains the largest component of total ABSSSI treatment cost. 
Utilization of linezolid and daptomycin increased the pharmacy or OPAT costs.
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Objectives: To examine the economic burden and health care utilizations 
of patients diagnosed with the hepatitis B virus (HBV) in the U.S. veteran 
population. MethOds: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets from October 1, 2008 to 
September 30, 2012. Patients diagnosed with HBV were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM 070.22, 070.23, 
070.32, 070.33, V02,61) diagnosis codes. The first diagnosis date was defined as the 
index date. A group of patients of the same age, region, gender and index year but 
without HBV infection were identified and matched by baseline Charlson Comorbidity 
Index (CCI) as the comparison group. A 1-year continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, including 
health care costs and utilizations, were compared between the HBV and compara-
tor groups using 1:1 propensity score matching. Results: A total of 9,718 patients 
were identified for the HBV and comparison cohorts. After applying a 1:1 matching, 
a total of 3,093 patients were matched from each cohort, and the baseline character-
istics were proportionate. Patients diagnosed with HBV infection were more likely to 
report higher health care utilizations, including inpatient (28.74% vs. 3.3%, p< 0.01), 
emergency room (25.67% vs. 8.3%, p< 0.01), physician office (98.60% vs. 62.75%) and 
pharmacy visits (88.23% vs. 63.65%, p< 0.01). The risk-adjusted health care costs were 
also higher for patients infected with HBV due to increased inpatient ($10,481 vs. $804, 
p< 0.01), emergency room ($382 vs. $80, p< 0.01), physician office ($4,635 vs. $1,678, 
p< 0.01), and pharmacy visits ($1,166 vs. $398, p< 0.01) resulting in higher total costs 
($16,909 vs. $3,045, p< 0.01) relative to the comparator cohort. cOnclusiOns: During 
a period of 12 months, VHA patients diagnosed with HBV reported higher health care 
utilization and costs than their matched controls.
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Objectives: Since Greece came under the regime of IMF and signed the memo-
randum, several curtailments had to be made to various areas of the public sec-
tor. Drug treatment seems to be quite expensive. As part of the strict economic 
rules, Greek hospitals were obliged to reduce their health care costs. The phar-
macy of each hospital incurred considerable weight of this attempt. One of its 
implemented actions was the drugs’ price negotiation with the pharmaceuti-
cal companies. MethOds: In order to measure the effectiveness of this action, 
we performed a comparative study of the antibiotics used in 3 hospitals, PAGNI, 
Evaggelismos and Tzaneio. PAGNI and Evaggelismos are among the 5 biggest hos-
pitals of Greece (pharmaceutical budget around 40M€ ) while Tzaneio is a small 
